Singapore Exchange Limited 1Q FY2009 Financial Results

Similar documents
Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts

ASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012

Telekom Austria Group Results for the 1st Quarter May 27, 2003

1Q2017 法人說明會 Jun. 9, 2017

FY2016 1H Results. Cookpad Inc.

For personal use only

Korean Airlines Q Results

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

Group 1Q FY13 financial highlights

A world leader in allergy immunotherapy

For personal use only

FY2007 Consolidated Financial Overview

Endesa 1Q 2017 Results 09/05/2017

Consolidated: Financial Summary

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016

Supplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016

Q Investor Kit JANUARY-MARCH 2014

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-

EUROZ INVESTOR CONFERENCE

The Dental Corporation Opportunity

Q Investor Kit January December 2014

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

APPLIANCE TELECOMMUNICATIONS

For personal use only

Universal Biosensors, Inc.

Summary Statement of Financial Position (consolidated)

Investor Presentation. Q April 26, 2018

Summary of Results for the First Half of FY2015/3

artnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017

Slide 1. Investor presentation. London 5 February 2019

CENTRALE. Monetary. compared. domestic. million.

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

Singapore Press Holdings. 1Q FY12 Financial Results 10 January 2012

DELICA D:5 ACTIVE GEAR 0

Genomic Health. Kim Popovits, Chairman, CEO and President

Results Briefing. 15 ~ 17 May 2007

Q Investor Kit JANUARY-JUNE 2014

Putting ALK on the right growth trajectory

Q Investor Kit JANUARY-JUNE 2013

Investor Presentation June 2012 NASDAQ: CEMI

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

ECONOMIC EFFECTS OF SARS ON THE ASIA-PACIFIC CASE STUDY ASIAN REGION

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011

THIRD QUARTER REPORT 2011 (UNAUDITED)

Q Investor Kit JANUARY-MARCH 2013

May 6, 2008 First Quarter 2008 Results

Investor Update May 2016

Q2 INVESTOR KIT JANUARY-JUNE 2011

Forward-Looking Statements

Asia Illicit Tobacco Indicator 2016: Hong Kong. Prepared by Oxford Economics October 2017

Coloplast A/S. Investor presentation 1H 2005/06

For personal use only

CRS Report for Congress Received through the CRS Web

Telekom Austria Group Results for the First Quarter May 16, 2007

BALCHEM CORPORATION. Q Investor Relations Presentation

ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1

Business Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.

1Q 2015 Results A Positive Start to 2015

HILLENBRAND INDUSTRIES INC

BancAnalysts Association of Boston Conference Presentation. November 3, 2017

Financial Presentation

MARKET NEWS for pig meat

Designing a Smoke-Free Future

Investor Presentation

Effective Tobacco Tax Reform: Evidence from China

Results for the fiscal year ended March 31, 2018 Future management outlook. May 10, 2018 Takashige Negishi President and Representative Director

Investor Presentation. Q October 26, 2017

Company Overview February 26, 2019

The Global Economic Crisis and HIV Prevention and Treatment Programmes: Vulnerabilities and Impact. Executive Summary TRINIDAD AND TOBAGO

Results Briefing Junichi Yoshii President & Representative Director

Press release Regulated information

Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018

Investor Presentation

Report. Uganda Pharmaceutical Sector Scan JUNE 2010

NASDAQ: FHCO 2016 Annual Meeting

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011

Corporate Presentation Fourth Quarter 2017

Interim Report 1 January September 2017

Hong Leong Bank Berhad (97141 X) A Member of the Hong Leong Group. A Member of the Hong Leong Group ANNUAL REPORT 2008

6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Oral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development

FY07 Full Year Update & Overview

The acquisition of Fortitech

MDxHealth. Excellent Buy Opportunity. Research Note.

Investor Presentation

Review of Half Year 2010

A GLOBAL LEADER IN PERSONALIZED NUTRITION

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS

A world leader in allergy immunotherapy

HONG LEONG TOP YIELD ACCOUNT TERMS & CONDITIONS ( T&Cs )

1Q 2014 Earnings Release

Small-Cap Research. Celator Pharma (CPXX-NASDAQ)

Forward Looking Information

Transcription:

Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1

1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008 Strong growth in net derivatives clearing revenue Expenses fell with lower variable bonus provision Operating leverage improved to 157% 2

Q1 FY09 vs Q1 FY08 Drop from record quarter In (S$M) 1Q FY09 1Q FY08 Y o Y Change Securities Market Revenue 74.4 141.1 47.3% Net Derivatives Clearing Revenue 46.1 37.3 23.6% Stable Revenue 37.7 41.2 8.6% Operating Revenue 158.2 219.7 28.0% Operating Expenses 53.4 58.3 8.3% Operating Profit 104.8 161.4 35.0% Other gains/ (losses) (1.6) (1.0) NM Net Profit after tax 84.5 130.0 35.0% ROE in % (quarterly figure) 9.1* 21.3 12.2% * The 1Q FY2009 ROE figure is relatively lower compared to 1Q FY2008 because of the later timing of this year s Annual General Meeting of which the final dividend for FY2008 was approved. If the proposed dividend had been removed from the equity base as per 1Q FY2008, the ROE would be 13.6%. 3

Q1 FY09 vs Q4 FY08 Flat operating profit In (S$M) 1Q FY09 4Q FY08 Q o Q Change Securities Market Revenue 74.4 90.2 17.5% Net Derivatives Clearing Revenue 46.1 41.4 11.4% Stable Revenue 37.7 40.4 6.8% Operating Revenue 158.2 172.0 8.0% Operating Expenses 53.4 68.4 21.9% Operating Profit 104.8 103.7 1.1% Other gains/ (losses) (1.6) 4.3 NM Net Profit after tax 84.5 90.4 6.5% ROE in % (quarterly figure) 9.1* 10.1 1.0% * The 1Q FY2009 ROE figure is relatively lower compared to 1Q FY2008 because of the later timing of this year s Annual General Meeting of which the final dividend for FY2008 was approved. If the proposed dividend had been removed from the equity base as per 1Q FY2008, the ROE would be 13.6%. 4

Financial Highlights (in S$M) 220 190 204 157 173 172 158 90 87 109 121 104 125 89 111 ** 130 *** 122 102 90 85 45 36 37 43 50 49 55 55 48 46 64 * 49 56 60 58 61 53 68 53 1Q FY06 2Q FY06 3Q FY06 4Q FY06 1Q FY07 2Q FY07 3Q FY07 4Q FY07 1Q FY08 2Q FY08 3Q FY08 4Q FY08 1Q FY09 Operating Revenue Net Profit After Tax Operating Expenses * Excludes the S$45.0 million write back of allowance for impairment on SGX Centre ** Excludes the S$65.5 million gain on disposal of SGX Centre *** Excludes the S$34.0 million distribution from SGX DT Compensation Fund 5

Operating Leverage (in S$M) 576 769 450 Operating Leverage* 1Q FY09 157% 4Q FY08 120% 408 326 1Q FY08 135% FY08 132% 208 96 104 184 Stable revenue 117 133 211 156 163 Net derivatives clearing revenue 141 241 90 74 * Operating 38 42 46 41 58 68 40 38 FY06 FY07 FY08 1Q FY08 4Q FY08 1Q FY09 220 Securities market revenue 172 Operating expenses 158 53 FY07 119% FY06 108% Leverage = Coverage of total operating expenses by derivatives revenue and stable revenue 6

Revenue (S$M) Derivatives Revenue 180 160 140 120 100 80 60 40 96 117 23 20 15 156 25 20 17 11 10 11 7 41 33 24 20 34 36 42 0 Other products & services Structured warrants MSCI Singapore CNX Nifty MSCI Taiwan Nikkei 225 0 37 6 7 3 6 4 5 5 5 8 4 6 10 11 10 12 9 13 FY06 FY07 FY08 1Q FY08 4Q FY08 1Q FY09 41 46 1Q FY09 on 4Q FY08 11% 21% increase in futures trading volume 7

Stable Revenue 180 160 140 120 100 80 60 40 20 0 (S$M) 104 15 8 14 19 26 22 133 19 7 18 23 31 35 163 18 9 23 29 42 42 Others Membership fees Terminal & Connection fees Price information fees Listing fees Account Main. & Corporate Action fees 41 40 38 6 2 3 2 3 6 5 2 6 8 8 8 10 11 10 11 11 9 FY06 FY07 FY08 1Q FY08 4Q FY08 1Q FY09 1Q FY09 on 4Q FY08 7% 20% decrease in account maintenance & corporate action fees 8

Operating Expenses Highlights 25.0 20.0 15.0 10.0 5.0 S$M 1Q FY08 4Q FY08 1Q FY09 14.7 14.3 13.6 14.6 13.2 11.5 8.5 9.3 5.8 5.7 5.7 3.7 3.3 3.5 5.0 12.1 20.1 15.5 1Q FY09 on 4Q FY08 22% 61% decrease in variable bonus 0.0 St af f Cost s (excl VB) Variable Bonus Syst em Maint. & Depreciat ion Cost f or processing & Ot hers * Rent al royalt ies * includes share based payment expense, rental and maintenance of premises, professional charges, marketing & travelling, communication charges, fees to MAS for transfer of participant supervision function, net foreign exchange loss/ gain, net loss on disposal of property, plant and equipment and software, and other operating expenses. 9

Performance at a Glance FY2006 FY2007* FY2008** 1Q FY2009 Return on Equity 32.0% 37.5% 49.7% 36.4%*** Cost to Income 45.1% 36.6% 31.2% 33.7% Net Profit Margin 44.6% 52.5% 56.8% 53.9% Regular dividend (Net) Base (cents per share) Variable (cents per share) 16.2 6.0 10.2 36.0 8.0 28.0 38.0 12.0 26.0 3.5 * FY2007 figures exclude the writeback of allowance for impairment on SGX Centre and gain on disposal of SGX Centre ** FY2008 figures exclude distribution from SGX DT Compensation Fund *** Annualised figure. The 1Q FY2009 ROE figure is relatively lower compared to 1Q FY2008 because of the later timing of this year s Annual General Meeting of which the final dividend for FY2008 was approved. If the proposed dividend had been removed from the equity base as per 1Q FY2008, the ROE would be 13.6%. The annualised ROE would be 54.4%. 10

Building An Enduring Marketplace Asian Gateway Domestic Growth Asian Listing Platform Structured Products Risk Management Centre Singapore Equity Derivatives Partnerships & Alliances Retail Penetration Post Trade Processing Hub Market Oriented Regulation Operational & Technology Efficiency Customer focused Organisation Delivery Excellence 11

Connections of the Asian Gateway Asian Gateway Capital Raising Platforms Risk Management Centre Xinhua A50 Futures MSCI Taiwan Futures CNX Nifty Index Futures Nikkei Index Futures Euroyen Futures Structured Warrants MSCI India ETF S&P Nifty ETF Japan, Korea & ASEAN ETF Structured Warrants 217 listings: 150 China 49 Hong Kong 18 Taiwan Greater China 5 listings & 9 Global Depository Receipts (GDRs) India 64 listings: 55 S.E. Asia 7 Japan 2 Korea Rest of Asia As at 30 Sep 08 12

Asian Gateway Domestic 1Q FY09: 52% (4Q FY08: 52%) Asian Gateway 1Q FY09: 48% (4Q FY08: 48%) Derivatives Securities $11M 1Q FY09: 7% (4Q FY08: 6%) $71M 1Q FY09: 45% (4Q FY08: 46%) $45M 1Q FY09: 28% (4Q FY08: 25%) $31M 1Q FY09: 20% (4Q FY08: 23%) * Internal estimates 13

Securities Trading Activity 190 1Q FY09 4Q FY08 Change 190 170 Value (S$B) SDAV (S$B) 83.5 1.27 101.9 1.62 18.0% 21.7% 170 Trading Value ($ Billion) 150 130 110 90 70 Volume shares (in Billion shares) 53.9 50 30 10 2QFY01 3QFY01 4QFY01 1QFY02 2QFY02 3QFY02 4QFY02 1QFY03 2QFY03 3QFY03 4QFY03 1QFY04 2QFY04 3QFY04 4QFY04 1QFY05 2QFY05 3QFY05 4QFY05 1QFY06 2QFY06 3QFY06 4QFY06 1QFY07 2QFY07 3QFY07 4QFY07 1QFY08 2QFY08 3QFY08 4QFY08 1Q FY09 68.4 21.2% 150 130 110 90 70 Trading Volume (Billion Shares) 50 30 10 Trading Value Trading Volum e 14

Market Access Products ETFs 2,500 2,000 1,500 1,000 500 0 2,191 812 622 805 62 226 FY06 FY07 FY08 1Q FY08 4Q FY08 1Q FY09 Traded value of ETFs: 277% Jan to Sep 2008: S$2.2B Jan to Sep 2007: S$584M Currently, the 19 SGX listed ETFs offer exposure to: Greater China, India, Hong Kong, Japan, Korea, ASEAN, Taiwan, Gold, Commodities 15

Growth in Futures Volumes 1Q FY09 4Q FY08 1Q FY09 on 4Q FY08 Total contracts (in millions) 17.4 14.4 20.5% 8.0 7.0 Top 4 contracts 7.2 Million Contracts 6.0 5.0 4.0 3.0 2.0 1.0 0.0 5.6 4.1 3.2 1.0 4.5 4.1 1.2 1QFY04 2QFY04 3QFY04 4QFY04 1QFY05 2QFY05 3QFY05 4QFY05 1QFY06 2QFY06 3QFY06 4QFY06 1QFY07 2QFY07 3QFY07 4QFY07 1QFY08 2QFY08 3QFY08 4QFY08 1QFY09 Nikkei MSCI TW MSCI SG CNX Nifty 16

Single Stock Derivatives Target launch: November 2008 SSDs are forward contracts traded on the SGX with a 35 day cycle. Also known as Extended Settlement (ES) contracts ES contracts on 50 stocks initially (both index and non index stocks) Margins of up to 5 to 20% of contract value Targeted at retail investors who can now long and short selected stocks listed on SGX with this product To plug the gap in the domestic derivatives revenue (7% of total revenues in 1Q FY2009) 17

Integrated Risk Management Practices of SGX as a Central Counterparty (CCP) Monitoring of Financial Resources & Supervision Of Clearing Members Integrated Risk Management Practices of a CCP Margins & Collateral Management Daily Monitoring Of Risk Exposures Efficient Clearing & Settlement Clearing Fund Resources 18

Summary Derivatives market Robust growth in derivatives market Single stock derivatives to be introduced in November 2008 Securities market SDAV above S$1 billion/ day Financials Cost management Other Key Developments SGX Prime launched on 13 October 2008 Technology refresh 19